Beyond Facials and Prejuvenation: How Medical Skin Boosters Improve Early Skin Ageing, Air-Con Dryness and Tired-Looking Skin

Most people who eventually ask about skin boosters do not start there. They start by describing skin that looks 'tired' rather than lined — a bit dull, a bit dry, less resilient than it used to be — and by mentioning that a facial helps for a few days before the effect quietly fades. That fading is not a failure of the facial. It is a sign that the problem being addressed sits deeper than a facial is designed to reach.

A medical skin booster is a series of small injections — typically non-cross-linked or lightly cross-linked hyaluronic acid, sometimes combined with amino acids or, in a related but distinct category, polynucleotides — delivered into the superficial-to-mid dermis to support hydration and skin quality directly. This distinguishes it clearly from a volumising dermal filler, which sits deeper and addresses structural loss rather than surface quality.

What early skin ageing actually looks like

Well before deeper wrinkles or structural volume loss become visible, skin typically goes through a quieter phase: reduced water-holding capacity, a duller and less even tone, and a loss of the slight bounce healthy skin has when pressed. This reflects both intrinsic ageing and cumulative photoaging acting together on the skin's structural and functional layers, and it is a distinct stage from the deeper collagen and fat-compartment changes addressed elsewhere.

Why facials tend to plateau

A facial works largely at the surface — exfoliation, massage, and temporary topical hydration — which explains both why it feels good immediately and why the effect is short-lived. It does not meaningfully change the dermis's own capacity to hold water or support itself, which is the layer actually responsible for the 'tired' quality being described. This is the same surface-versus-structure distinction that applies to rebuilding the skin barrier, just one layer further down, and it is worth judging on the same longer, biologically realistic timeline rather than after a single session.

What a skin booster does differently

Non-cross-linked hyaluronic acid delivered into the dermis integrates with the surrounding tissue, draws in and holds water directly at the layer that needs it, and appears to support fibroblast activity over a course of sessions — early pilot studies measuring skin elasticity directly found a measurable improvement over several treatments rather than after just one.

• Improved hydration and water-holding capacity at the dermal level, not just the skin surface
• Measurable gains in elasticity that accumulate across a course of sessions rather than appearing after a single visit
• A texture and tone effect that develops gradually, in line with the tissue's own remodelling timeline
• A typical protocol of several sessions spaced weeks apart, followed by periodic maintenance rather than a single treatment

Where polynucleotides fit in

Polynucleotide-based skin boosters work through a related but biologically distinct route, drawing on tissue-repair signalling rather than hyaluronic acid's water-binding properties. Interest in this category has grown quickly, but a recent systematic review of the evidence found the existing studies to be of generally low-to-moderate quality — encouraging early results, but not yet the weight of evidence behind better-established hyaluronic acid-based approaches. That distinction is worth stating plainly rather than glossing over.

The goal is not to look treated. It's to stop looking tired — and those are different enough goals that they call for different tools.

How this differs from 'prejuvenation'

'Prejuvenation' has become a marketing shorthand for treating early, largely to pre-empt ageing that has not yet occurred. The more useful question is not how early a treatment starts, but whether it is addressing a genuine, present change in skin quality or simply following a trend applied uniformly regardless of what a particular person's skin actually needs — the same evidence-before-trend standard that governs decision-making elsewhere in aesthetic medicine applies here too.

Who is a reasonable candidate

• Early dryness, dullness, or loss of elasticity without significant structural volume loss
• A skin-quality concern — texture, tone, hydration — rather than a change in facial proportion or structure
• A willingness to commit to a short course of sessions and realistic, gradual expectations rather than an immediate transformation
• No unaddressed structural change, since [skin-level quality and deep-structure volume are different problems](/journal/collagen-and-the-midface) that call for different assessments

The clearest sign that a skin booster is the right tool is a skin-quality concern in the absence of a structural one. Where both are present, the structural change is usually assessed and addressed first.

The same willingness to separate a promising mechanism from a proven skin-specific outcome applies to NMN and NAD+ precursors — a supplement category with strong underlying cell biology but, so far, mostly preclinical evidence for the skin claims made about it.